Press Releases

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas

Posted on February 24, 2014

Grant to Be Used to Fund Ongoing Clinical Trials for Brain Cancer HOUSTON, TX – February 24, 2014 — DNAtrix Inc., a biotech company focusing on the development of oncolytic.. read more

DNAtrix Has Been Named as One of the “Top Advanced Therapies Projects to Watch” and Will Present at the Therapeutic Area Partnerships

Posted on November 18, 2013

Houston, TX – (BUSINESS WIRE – November 18, 2013) – DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that the lead clinical.. read more

DNAtrix Announces Treatment of First Patient in Study with Recurrent Glioblastoma Using DNX-2401 and Temozolomide

Posted on November 14, 2013

Houston, TX – (BUSINESS WIRE – November 14, 2013) – DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that the first patient.. read more

DnaTrix, Inc. To Present Clinical Study Results For DNX-2401 (DELTA 24-RGD), A Conditionally Replication-Competent Adenovirus

Posted on June 18, 2013

Dr. Frank Tufaro to present first-in-human clinical data demonstrating DNX-2401’s ability to treat patients with malignant brain tumors HOUSTON, TX. – June 18, 2013 – DNAtrix Inc., experts in oncolytic.. read more

Alcyone Lifesciences and DNAtrix, Inc., to Collaborate on Unique Delivery System to treat Brain Tumors

Posted on March 26, 2013

Collaboration announced today between Alcyone Lifesciences and DNAtrix, Inc. March 20th, 2013 Concord, MA/Houston, TX -(BUSINESS WIRE)–Alcyone Life Sciences, Inc., a privately held biopharmaceutical device company focusing on developing products.. read more